Lv4
440 积分 2023-05-08 加入
[Immune checkpoint inhibitors-related hyperprogressive disease: a case report]
22小时前
已完结
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
22小时前
已完结
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
3天前
已完结
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
21天前
已完结
[Progress on the research of liver diseases in 2022]
2个月前
已完结
Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness
2个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
2个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
2个月前
已完结
Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study
4个月前
已完结
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial
4个月前
已完结
皖公网安备34019202002308
